Publications by authors named "Mercedes Salgado"

Claim this Profile
G
Genomic diversity and BCL9L mutational status in circulating tumor cells predict overall survival in metastatic colorectal cancer.
Joao M Alves, Nuria Estévez-Gómez, Roberto Piñeiro, Laura Muinelo-Romay, Patricia Mondelo-Macía, Mercedes Salgado

Cell Oncol (Dordr)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design.
Mercedes Salgado, Juan de la Camara-Gómez, Ignacio García-Escobar, Renata-Carola Álvarez-Llosa, Paula González-Villarroel

BMC Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer-associated venous thromboembolism and its impact on survival in the ONCOTHROMB12-01 cohort study.
Bárbara Lobato-Delgado, Magdalena Ruiz, Carme Font, Vanessa Pachón, Victoria Castellón, Mercedes Salgado

Int J Cardiol Heart Vasc· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of risk prediction scores including all types of cancer-associated thrombosis.
Irene González Caraballo, Bárbara Lobato Delgado, Magdalena Ruiz Zamorano, Mercedes Salgado, Vanessa Pachón

Clin Transl Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study.
Javier Trujillo-Santos, Ignacio García-Escobar, Mercedes Salgado, António Araújo, Eva Martínez-de-Castro

Oncologist· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancer.
Manuel Valladares-Ayerbes, Marta Toledano-Fonseca, Begoña Graña, Paula Jimenez-Fonseca, Gema Pulido-Cortijo, Mercedes Salgado

BMC Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study.
Yolanda Escobar, Avinash Ramchandani, Mercedes Salgado, Alfredo Castillo-Trujillo, Eva Martínez de Castro

Clin Transl Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.
Andrés Muñoz, Cihan Ay, Ella Grilz, Sonia López, Carme Font, Mercedes Salgado

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of Mutations in Cell-Free DNA of Patients with Tissue Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study.
Manuel Valladares-Ayerbes, Pilar Garcia-Alfonso, Jorge Muñoz Luengo, Paola Patricia Pimentel Caceres, Oscar Alfredo Castillo Trujillo, Mercedes Salgado

Cancers (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of capture methods for genomic profiling of circulating tumor cells in colorectal cancer.
Joao M Alves, Nuria Estévez-Gómez, Monica Valecha, Sonia Prado-López, Laura Tomás, Mercedes Salgado

Genomics· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venous Thromboembolism In Cancer Patients: "From Evidence to Care".
Mercedes Salgado, Elena Brozos-Vázquez, Begoña Campos, Paula González-Villarroel, María Eva Pérez

Clin Appl Thromb Hemost· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
Elena Élez, María Auxiliadora Gómez-España, Cristina Grávalos, Pilar García-Alfonso, María José Ortiz-Morales, Mercedes Salgado

Br J Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing an Expert Consensus on Key Indicators of the Quality of Life among Breast Cancer Survivors: A Modified Delphi Study.
Izidor Mlakar, Simon Lin, Jama Nateqi, Stefanie Gruarin, Lorena Diéguez, Mercedes Salgado

J Clin Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients-centered SurvivorShIp care plan after Cancer treatments based on Big Data and Artificial Intelligence technologies (PERSIST): a multicenter study protocol to evaluate efficacy of digital tools supporting cancer survivors.
Izidor Mlakar, Simon Lin, Ilona Aleksandraviča, Krista Arcimoviča, Jānis Eglītis, Ángel Salgado Barreira, Mercedes Salgado

BMC Med Inform Decis Mak· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study.
Ruth Vera, María Luisa Gómez, Juan Ramón Ayuso, Joan Figueras, Pilar García-Alfonso, Mercedes Salgado

Cancers (Basel)· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Ruth Vera, Elena Mata, Encarna González, Ignacio Juez, Vicente Alonso, Mercedes Salgado

Int J Colorectal Dis· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
Pilar García-Alfonso, Manuel Benavides, Esther Falcó, Andrés Muñoz, Auxiliadora Gómez, Mercedes Salgado

Oncologist· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Ana Fernández, Mercedes Salgado, Adelaida García, Elvira Buxò, Ruth Vera

BMC Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer.
Andrés J Muñoz Martín, Israel Ortega, Carme Font, Vanesa Pachón, Victoria Castellón, Mercedes Salgado

Br J Cancer· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer.
Andrés Muñoz Martín, Manuel Hidalgo, Rafael Alvarez, Virginia Arrazubi, Joaquina Martínez-Galán, Mercedes Salgado

J Cancer· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Juan Turnes, Roberto Díaz, Manuel Hernandez-Guerra, Mariano Gómez, Lluís Castells, Mercedes Salgado

Gastroenterol Hepatol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Ann Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).
Julen Fernandez-Plana, Carlos Pericay, Guillermo Quintero, Vicente Alonso, Antonieta Salud, Mercedes Salgado

BMC Cancer· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
Carlos Gomez-Martín, Fernando Lopez-Rios, Jorge Aparicio, Jorge Barriuso, Rocio García-Carbonero, Mercedes Salgado

Cancer Lett· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study.
Mercedes Salgado, Margarita Reboredo, Juan Carlos Mendez, Guillermo Quintero, María Luz Pellón

Anticancer Res· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis